Autopsy report · NCT00943553

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

“Terminated by Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Eisai Inc.

Sponsor type

Industry

Conditions

Acute Myelogenous Leukemia (AML)

Interventions

decitabine Induction Chemotherapy; Induction Chemotherapy

Participants

0

Sites

1

Countries

India

Trials that died the same way

• Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers
  “Sponsor Terminated” (96% match in meaning)
• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
  “Terminated due to the sponsor's decision.” (93% match in meaning)
• Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
  “Terminated by previous Sponsor decision” (92% match in meaning)
• ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
  “Terminated - Sponsor Decision” (91% match in meaning)
• Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
  “Terminated at the request of the financial sponsor.” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.